Biological E. Limited (BE) Secures WHO Emergency Use Listing for Corbevax COVID-19 Vaccine

Hyderabad-based vaccine manufacturer, Biological E. Limited (BE), has achieved a significant milestone by obtaining Emergency Use Listing (EUL) from the World Health Organization (WHO) for its Corbevax COVID-19 vaccine. This protein sub-unit platform-based vaccine, known for its safety and efficacy, has already received approval from India's Drugs Controller General for emergency use among adults, adolescents, and young children, as well as for use as a heterologous COVID-19 booster shot for adults aged 18 and above.

BE's Managing Director, Mahima Datla, highlighted the importance of the WHO's EUL in expanding the vaccine's reach to countries facing fiscal constraints in their fight against COVID-19. BE has already supplied 100 million doses of Corbevax to the Central Government of India as part of the COVID-19 immunization campaign for children aged 12 to 14.

Beyond Corbevax, BE is actively engaged in developing the next-generation COVID-19 vaccine based on the XBB1.5 variant of the SARS-CoV-2 virus. This new vaccine is designed to align with WHO TAG-CO-VAC recommendations and has completed crucial pre-clinical animal studies, showing promise in protecting against currently circulating variants. The company has received final approval to commence clinical trials for this advanced vaccine in India, further emphasizing its commitment to global vaccine accessibility and innovation.